News

Filter

Current filters:

Gastro-intestinalsSanofi

Sanofi and Regeneron's alirocumab achieves positive Phase III results in reducing LDL

Sanofi and Regeneron's alirocumab achieves positive Phase III results in reducing LDL

19-11-2014

French drug major Sanofi and partner Regeneron Pharmaceuticals have reported results of six Phase III…

alirocumabBiotechnologyGastro-intestinalsRegeneron PharmaceuticalsResearchSanofi

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

Sanofi US in deal to commercialize PA8140/PA32540

04-09-2013

The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

Sanofi presents benefits of semuloparin; Zaltrap improves colorectal cancer survival

07-06-2011

French drug major Sanofi (Euronext: SAN) announced results at the American Society of Clinical Oncology…

Cardio-vascularGastro-intestinalsOncologyPharmaceuticalRegeneronResearchSanofisemuloparinZaltrap

Back to top